Albert Einstein College of Medicine

The New York Center for Rare Diseases at Montefiore to Partner with GeneDx, PacBio and Google Health to Increase Genomic Testing Options for Bronx Families

Retrieved on: 
Wednesday, November 8, 2023
Albert Einstein College of Medicine, Center of excellence, DSM-IV codes, Genetic testing, Rare, RNA, Hope, Genetics, Research, NORD, Children's Hospital at Montefiore, Environment, Disease, Division, National Organization for Rare Disorders, Abraxis BioScience, FACMG, Partnership, CHAM, Google Health, GeneDx, Google AI, DNA encryption, Patient, Hospital, Pediatrics, DNA, Medical imaging, Vaccine, Genomics, Montefiore, The Bronx

BRONX, N.Y., Nov. 8, 2023 /PRNewswire/ -- The New York Center for Rare Diseases (NYCRD) at Montefiore, recognized as a Center of Excellence by the National Organization for Rare Disorders (NORD), is partnering with GeneDx, PacBio and Google Health to deliver genetic diagnoses for Bronx families living with rare diseases. The goal of the new partnership is to help identify the genetic causes of, and best treatments for rare diseases that have remained undiagnosed, despite using today's most advanced tests.

Key Points: 
  • On average, the search for a rare disease diagnosis takes five to seven years and can be fraught with misdiagnoses.
  • The focus of this research project on the Bronx in New York City adds a level of complexity to rare disease diagnostics.
  • "Our aim is to illuminate rare disease mysteries and bring answers and hope to families navigating the complexities of a rare disease."
  • Together with PacBio and Montefiore, we can help improve equity in genomics resources and help end long diagnostic odysseys for patients."

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Retrieved on: 
Thursday, October 26, 2023
Multiple myeloma, American Society of Clinical Oncology, American Society of Hematology, Clinical Cancer Research, Coronavirus Scientific Advisory Board, Albert Einstein College of Medicine, MD, Harry Oppenheimer Fellowship Award, Stanford Department of Electrical Engineering, SWOG, Stanford University Medical Center, Society, Memorial, International Society, Patient, ASCO, Nursing, Amyloidosis, Hematology, Hannover Medical School

LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.
  • Dr. Liedtke brings decades of experience in hematology/oncology clinical trials, clinical trial design, and thought leadership to Nexcella.
  • “We need more effective treatments to improve the outcomes for patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma,” said Dr. Liedtke.
  • We are excited to be working with Dr. Liedtke.”
    Dr. Liedtke is the Stanford University Medicine Cancer Center Program Lead, Hematology; Co-Director, Stanford Amyloid Center; Medical Director, Stanford Adolescent and Young Adult Program; and Member Leukemia Committee, Southwest Oncology Group.

Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Retrieved on: 
Thursday, October 26, 2023
Multiple myeloma, American Society of Clinical Oncology, American Society of Hematology, Clinical Cancer Research, MD–PhD, Coronavirus Scientific Advisory Board, Albert Einstein College of Medicine, MD, Harry Oppenheimer Fellowship Award, Stanford Department of Electrical Engineering, SWOG, Stanford University Medical Center, Society, Memorial, International Society, Patient, ASCO, Nursing, Amyloidosis, Hematology, Hannover Medical School

LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined the Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined the Nexcella Scientific Advisory Board.
  • Dr. Liedtke brings decades of experience in hematology/oncology clinical trials, clinical trial design, and thought leadership to Nexcella.
  • We are excited to be working with Dr. Liedtke.”
    Dr. Liedtke is the Stanford University Medicine Cancer Center Program Lead, Hematology; Co-Director, Stanford Amyloid Center; Medical Director, Stanford Adolescent and Young Adult Program; and Member Leukemia Committee, Southwest Oncology Group.
  • Dr. Liedtke completed her fellowship at Stanford University Medical Center and Memorial Sloan-Kettering Cancer Center, residency at the Albert Einstein College of Medicine, and received her medical degree from Medizinische Hochschule Hannover.

Findhelp Expands Work with NYC Providers and Health Systems Prior to Launch of the NY State 1115 Medicaid Waiver

Retrieved on: 
Thursday, October 26, 2023
Albert Einstein College of Medicine, Education, Housing, Population health, Health, Food, DOH, Medicare, New York State Department of Health, United Way, United Hospital Fund, State, Organization, Research, Dignity, SEIU, New York City Department of Health and Mental Hygiene, Hudson Valley, Transport, NYC Health + Hospitals, Health equity, Partnership, Aetna, Social, Centers for Medicare & Medicaid Services, Hospital, New Yorker, Community, Safety, Elevance Health, Health and Social Care Network, Family medicine, Patient, SCN, MediSys Health Network, CMS, Health insurance, Montefiore, Medicaid

NYC Health + Hospitals (H+H), the nation's largest municipal healthcare system, has partnered with findhelp to connect community members with social care services.

Key Points: 
  • NYC Health + Hospitals (H+H), the nation's largest municipal healthcare system, has partnered with findhelp to connect community members with social care services.
  • The main goals of the waiver are to improve health equity in the Medicaid program, and approval is expected in late fall 2023.
  • Findhelp is also excited to announce our new partnership with Montefiore, one of New York's premier academic health systems.
  • At a United Hospital Fund conference this summer, Amir Bassiri, the Medicaid Director for New York DOH, said that the 1115 Medicaid waiver will integrate social care with health care to support population health, improve health outcomes, and reduce health disparities.

St. Jude Children’s Research Hospital, ALSAC announce new board leaders

Retrieved on: 
Monday, October 16, 2023
American Academy of Orthopaedic Surgeons, Biomedical engineering, Advance Auto Parts, William H. Harris (orthopaedic surgeon), Commerce, National Cancer Institute, Health, Survival, DSM-IV codes, Social media, Rady, Research, UCSD, Infection, NCI-designated Cancer Center, Molecule, Albert Einstein College of Medicine, Montefiore, Columbia University, Greater Boston, History, Neuroscience, Volunteering, Del Monte Foods, International, OfficeMax, Sutter Health, Sickle cell disease, University, Cancer, Stitch Fix, Williams-Sonoma, Inc., Physician, Yale University, National Cancer Research Institute, American Academy, Signet Jewelers, Hospital, Orthopedic surgery, ALSAC, University of California, San Diego, Science, Child, Management, Nursing, Jude the Apostle, Pediatrics

Memphis, Oct. 16, 2023 (GLOBE NEWSWIRE) -- St. Jude Children’s Research Hospital ® and ALSAC , its fundraising and awareness organization, announced new leaders of the St. Jude Board of Governors and ALSAC Board of Directors today.

Key Points: 
  • Memphis, Oct. 16, 2023 (GLOBE NEWSWIRE) -- St. Jude Children’s Research Hospital ® and ALSAC , its fundraising and awareness organization, announced new leaders of the St. Jude Board of Governors and ALSAC Board of Directors today.
  • Having chaired the ALSAC Board of Directors from 2019 to 2021, she is now the first woman to have chaired both Boards.
  • “Sharon’s wise counsel and vast business experience will also be a great asset as vice chair of the ALSAC Board.
  • To learn more, visit stjude.org , read St. Jude Progress blog , and follow St. Jude on social media at @stjuderesearch .

Board-certified Dermatologist Dr. Blair Rose Announces the Launch of Skincare Junkie

Retrieved on: 
Tuesday, October 3, 2023
Weill Cornell Medical Center, Rosacea, Montefiore Medical Center, University, Shareasale, Helsinki University Central Hospital, Business Insider, Salicylic acid, Cowra breakout, Dermatitis, University of California, Irvine School of Medicine, Antioxidant, Merchant, Skin cancer, Pediatric Dermatology, Vogue, Skin, Phthalate, Women's health, American Academy, Hyaluronic acid, Acne, Multimedia, FAAD, Pore, Psoriasis, John Foster Dulles, Journal, PHA, Publication, PRP, Patient, Irritation, Confusion, Albert Einstein College of Medicine, Ceramide, Cosmetics, Dermatology, Elle, MD, Medicine

NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Board certified and award-winning dermatologist Dr. Blair Rose is excited to share the launch of Skincare Junkie , a skincare line that utilizes powerful and clinically proven ingredients in just the right combinations and concentrations to solve common skin problems.

Key Points: 
  • NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Board certified and award-winning dermatologist Dr. Blair Rose is excited to share the launch of Skincare Junkie , a skincare line that utilizes powerful and clinically proven ingredients in just the right combinations and concentrations to solve common skin problems.
  • Dr. Rose created Skincare Junkie out of necessity when she noticed countless patients developing breakouts and skin irritation from popular skincare products.
  • "I needed to create a line of non-toxic, hypoallergenic skincare that I would feel confident suggesting to my patients and that they would enjoy using" says Dr. Rose.
  • Blair Murphy Rose, MD, FAAD , is an award-winning board-certified dermatologist seeing patients in NYC and a clinical instructor of dermatology at the Weill Cornell Medical Center.

Atomwise Announces Nomination of its First AI-Driven Development Candidate Focused on TYK2 Inhibition and Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer

Retrieved on: 
Tuesday, October 3, 2023
Other Health, Software, Research, Pharmaceutical, Data Management, Technology, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, Lupus, Psoriatic arthritis, University, Deep learning, Multimedia, CMO, Doctor of Philosophy, Psoriasis, Inflammatory bowel disease, MD, Patient, University of Washington Department of Global Health, TYK2, Internal medicine, Drug discovery, AI, Albert Einstein College of Medicine, IND, Pharmaceutical industry, Rheumatology

Atomwise , a leader in using AI for small molecule drug discovery, today announced the nomination of its first AI-driven development candidate focused on TYK2 inhibition and the appointment of Neely Mozaffarian, MD, PhD as Chief Medical Officer.

Key Points: 
  • Atomwise , a leader in using AI for small molecule drug discovery, today announced the nomination of its first AI-driven development candidate focused on TYK2 inhibition and the appointment of Neely Mozaffarian, MD, PhD as Chief Medical Officer.
  • Dr. Mozaffarian brings over 25 years of immunology and clinical research experience to the role of Chief Medical Officer at Atomwise.
  • View the full release here: https://www.businesswire.com/news/home/20230927754050/en/
    Dr. Mozaffarian will drive Atomwise’s first development candidate, an orally bioavailable and allosteric TYK2 inhibitor discovered by leveraging Atomwise’s proprietary AI drug discovery platform AtomNet®, into clinical trials.
  • TYK2 is a key mediator in cytokine signaling pathways linked to a broad range of immune-mediated inflammatory conditions.

Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer

Retrieved on: 
Friday, September 29, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Harvard School of Dental Medicine, Therapy, Cancer, Breast, PI3K, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Public health, Enzalutamide, Patient, Yale University, Phosphine, Albert Einstein College of Medicine, Ovarian cancer, Publius Cornelius Arvina, BLA, Pharmaceutical industry, EU, Gemtuzumab ozogamicin, Pfizer

Faeth Therapeutics , a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer.

Key Points: 
  • Faeth Therapeutics , a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer.
  • Debbie comes to Faeth with years of experience in clinical development and medical affairs, which we look to leverage as we continue the clinical development of our lead assets,” said Anand Parikh, J.D., Chief Executive Officer of Faeth Therapeutics.
  • We aim to empower patients to participate in their care with a science-based, precision approach to nutrition that will enhance their anti-tumor armamentarium,” said Debbie Chirnomas, M.D., M.P.H., Chief Medical Officer of Faeth Therapeutics.
  • “Faeth is a special company with a pioneering mindset based on outstanding science and is uniquely positioned to bring a radically new approach to cancer therapeutics for at-need patients.”

Montefiore Einstein Comprehensive Cancer Center Unveils New Destination for Breast Care

Retrieved on: 
Thursday, September 28, 2023
Albert Einstein College of Medicine, BOLD, GE HealthCare, Lymphedema, Surgical oncology, Radiation, Surgeon, Hair loss, 3D, Clinical trial, GE, Woman, Research, Element, Anesthesia, Genetic counseling, Incidence, Montefiore, Breast, Patient, Physician, Head, Diagnosis, Health, Mammography, Breast cancer, Medical imaging, Birth control, Pharmaceutical industry, Radiology

BRONX, N.Y., Sept. 28, 2023 /PRNewswire/ -- Yesterday, Montefiore Einstein Comprehensive Cancer Center (MECCC) opened a new state-of-the-art breast center at the Hutchinson Metro Center at 1250 Waters Place. The center is home to some of the nation's top breast cancer physicians, surgeons and researchers. It offers screening studies, advanced imaging, minimally invasive surgery, plastic & reconstructive surgery, a high-risk breast cancer prevention and lymphedema prevention program, as well as genetic counseling under one roof. Services like medical & radiation oncology, nutrition, and access to MECCC's Bronx Oncology Living Daily (BOLD) wellness and support program, are also available. The goal of the breast center is to provide every patient with an unparalleled level of evaluation and care.

Key Points: 
  • Comprehensive Breast Services & the Most Advanced Technology Available in a New, Healing Environment
    BRONX, N.Y., Sept. 28, 2023 /PRNewswire/ -- Yesterday, Montefiore Einstein Comprehensive Cancer Center (MECCC) opened a new state-of-the-art breast center at the Hutchinson Metro Center at 1250 Waters Place.
  • The center is home to some of the nation's top breast cancer physicians, surgeons and researchers.
  • The goal of the breast center is to provide every patient with an unparalleled level of evaluation and care.
  • For more information about the breast center and MECCC's research and patient care, including its High-Risk Prevention and Surveillance program, visit cancer.montefioreeinstein.org.

World-Renowned Orthopaedics Pioneer Joseph D. Zuckerman, MD, Receives Lifetime Achievement Award

Retrieved on: 
Wednesday, September 20, 2023
Glenoid labrum, Albert Einstein College of Medicine, Surgeon, William H. Harris (orthopaedic surgeon), Education, Lifetime Achievement Emmys, Professional, NYU, American Academy, NYU Langone Health, OSET, Patient, Walter, American Academy of Orthopaedic Surgeons, BPS Barbara Wilson Lifetime Achievement Award, Faculty, Knowledge, Extremities, Health, Orthopedic surgery, MPH, Nursing, Medical device, MD

"In our 13th year of the Orthopaedic Summit, I couldn't be prouder to present the Lifetime Achievement Award to Joseph D. Zuckerman," said Kevin Plancher, MD, MPH, FAOA, FAAOS, Founder of the Orthopaedic Summit, Clinical Professor of Orthopaedics at Albert Einstein College of Medicine.

Key Points: 
  • "In our 13th year of the Orthopaedic Summit, I couldn't be prouder to present the Lifetime Achievement Award to Joseph D. Zuckerman," said Kevin Plancher, MD, MPH, FAOA, FAAOS, Founder of the Orthopaedic Summit, Clinical Professor of Orthopaedics at Albert Einstein College of Medicine.
  • "I am honored OSET chose to award me the Lifetime Achievement award," Zuckerman said.
  • I would like to thank my colleagues for their passion and sharing the same vision to advance the field of orthopaedics.
  • "Dr. Zuckerman's extensive knowledge, leadership and professionalism exemplifies why he is a recipient of the Lifetime Achievement award," said Exactech Vice President of Extremities Marketing Emery Patton.